This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kokai-Kun, J. F.
Right arrow Articles by Mond, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kokai-Kun, J. F.
Right arrow Articles by Mond, J. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1589-1597, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1589-1597.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model

John F. Kokai-Kun,* Scott M. Walsh, Tanya Chanturiya, and James J. Mond

Biosynexus Incorporated, Gaithersburg, Maryland 20877

Received 31 October 2002/ Returned for modification 27 January 2003/ Accepted 29 January 2003

The anterior nares are a primary ecologic niche for Staphylococcus aureus, and nasal colonization by this opportunistic pathogen increases the risk of development of S. aureus infection. Clearance of S. aureus nasal colonization greatly reduces this risk. Mupirocin ointment is the current standard of care for clearance of S. aureus nasal colonization, but resistance to this antibiotic is emerging. Lysostaphin is a glycylglycine endopeptidase which specifically cleaves the cross-linking pentaglycine bridges in the cell walls of staphylococci. Lysostaphin is extremely staphylocidal (MIC at which 90% of isolates are inhibited, 0.001 to 0.064 µg/ml) and rapidly lyses both actively growing and quiescent S. aureus. This study demonstrates that a single application of 0.5% lysostaphin (actual dose, ~150 µg of lysostaphin), formulated in a petrolatum-based cream, dramatically reduces S. aureus nasal colonization in 100% of animals tested and eradicates S. aureus nasal colonization in 93% of animals in a cotton rat model. A single dose of lysostaphin cream is more effective than a single dose of mupirocin ointment in eradicating S. aureus nasal colonization in this animal model. The lantibiotic peptide nisin, which has potent in vitro antistaphylococcal activity, was ineffective in reducing staphylococcal nasal carriage in this model. Nasal colonization was not reduced after three treatments with 5% nisin (~1,500 µg/dose) in any of the treated animals. Lysostaphin formulated in cream may prove to be a superior alternative to mupirocin ointment for clearance of S. aureus nasal colonization.


* Corresponding author. Mailing address: Biosynexus Incorporated, 9119 Gaither Rd., Gaithersburg, MD 20877. Phone: (301) 987-1172. Fax: (301) 990-4990. E-mail: johnkun{at}biosynexus.com.


Antimicrobial Agents and Chemotherapy, May 2003, p. 1589-1597, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1589-1597.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Van Hekken, D. L., Wall, R. J., Somkuti, G. A., Powell, M. A., Tunick, M. H., Tomasula, P. M. (2009). Fate of lysostaphin in milk from individual cows through pasteurization and cheesemaking. J DAIRY SCI 92: 444-457 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Chanturiya, T., Mond, J. J. (2007). Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 60: 1051-1059 [Abstract] [Full Text]  
  • Stapleton, M. R., Horsburgh, M. J., Hayhurst, E. J., Wright, L., Jonsson, I.-M., Tarkowski, A., Kokai-Kun, J. F., Mond, J. J., Foster, S. J. (2007). Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of Staphylococcus aureus. J. Bacteriol. 189: 7316-7325 [Abstract] [Full Text]  
  • Oluola, O., Kong, L., Fein, M., Weisman, L. E. (2007). Lysostaphin in Treatment of Neonatal Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 51: 2198-2200 [Abstract] [Full Text]  
  • Kusuma, C., Jadanova, A., Chanturiya, T., Kokai-Kun, J. F. (2007). Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo. Antimicrob. Agents Chemother. 51: 475-482 [Abstract] [Full Text]  
  • Cosgrove, K., Coutts, G., Jonsson, I.-M., Tarkowski, A., Kokai-Kun, J. F., Mond, J. J., Foster, S. J. (2007). Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in Staphylococcus aureus. J. Bacteriol. 189: 1025-1035 [Abstract] [Full Text]  
  • Yang, X.-Y., Li, C.-R., Lou, R.-H., Wang, Y.-M., Zhang, W.-X., Chen, H.-Z., Huang, Q.-S., Han, Y.-X., Jiang, J.-D., You, X.-F. (2007). In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol 56: 71-76 [Abstract] [Full Text]  
  • Grundling, A., Missiakas, D. M., Schneewind, O. (2006). Staphylococcus aureus Mutants with Increased Lysostaphin Resistance.. J. Bacteriol. 188: 6286-6297 [Abstract] [Full Text]  
  • Schaffer, A. C., Solinga, R. M., Cocchiaro, J., Portoles, M., Kiser, K. B., Risley, A., Randall, S. M., Valtulina, V., Speziale, P., Walsh, E., Foster, T., Lee, J. C. (2006). Immunization with Staphylococcus aureus Clumping Factor B, a Major Determinant in Nasal Carriage, Reduces Nasal Colonization in a Murine Model. Infect. Immun. 74: 2145-2153 [Abstract] [Full Text]  
  • Grundling, A., Schneewind, O. (2006). Cross-Linked Peptidoglycan Mediates Lysostaphin Binding to the Cell Wall Envelope of Staphylococcus aureus.. J. Bacteriol. 188: 2463-2472 [Abstract] [Full Text]  
  • Borysowski, J., Weber-Dabrowska, B., Gorski, A. (2006). Bacteriophage endolysins as a novel class of antibacterial agents.. Exp. Biol. Med. 231: 366-377 [Abstract] [Full Text]  
  • Ochsner, U. A., Young, C. L., Stone, K. C., Dean, F. B., Janjic, N., Critchley, I. A. (2005). Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase. Antimicrob. Agents Chemother. 49: 4253-4262 [Abstract] [Full Text]  
  • Rouse, M. S., Rotger, M., Piper, K. E., Steckelberg, J. M., Scholz, M., Andrews, J., Patel, R. (2005). In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3187-3191 [Abstract] [Full Text]  
  • Kusuma, C. M., Kokai-Kun, J. F. (2005). Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3256-3263 [Abstract] [Full Text]  
  • Gonzalez-Zorn, B., Senna, J. P. M., Fiette, L., Shorte, S., Testard, A., Chignard, M., Courvalin, P., Grillot-Courvalin, C. (2005). Bacterial and Host Factors Implicated in Nasal Carriage of Methicillin-Resistant Staphylococcus aureus in Mice. Infect. Immun. 73: 1847-1851 [Abstract] [Full Text]  
  • Kruszewska, D., Sahl, H.-G., Bierbaum, G., Pag, U., Hynes, S. O., Ljungh, A. (2004). Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54: 648-653 [Abstract] [Full Text]  
  • Wu, J. A., Kusuma, C., Mond, J. J., Kokai-Kun, J. F. (2003). Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces. Antimicrob. Agents Chemother. 47: 3407-3414 [Abstract] [Full Text]  
  • von Eiff, C., Kokai-Kun, J. F., Becker, K., Peters, G. (2003). In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood. Antimicrob. Agents Chemother. 47: 3613-3615 [Abstract] [Full Text]